Research
Hormonal
Tirzepatide provides significant cardiovascular, hepatic, and renal benefits in obese patients, including improved lipid profiles, reduced blood pressure, and potential protection against NAFLD/NASH and CKD progression.
Beyond weight loss, Tirzepatide improves heart health by lowering blood pressure and cholesterol, and may protect the liver (NAFLD/NASH) and kidneys (CKD). These benefits are observed alongside weight loss but may also stem from direct hormonal effects.
GoodSupportsHIGH confidence
Tirzepatide treatment further reduces the levels of inflammatory markers... Tirzepatide has been shown in clinical trials to significantly lower both systolic and diastolic blood pressure... suggest a beneficial effect of tirzepatide therapy on NASH... tirzepatide may have a nephroprotective effect
Why this rating
Based on secondary endpoints of Phase 3 trials (SURPASS-4, SURPASS-5, Hartmann et al.).
Source
Tirzepatide - A Revolution in Obesity Treatment?
Aleksandra Jaroń et al. · Quality in Sport · 2024
DOI 10.12775/qs.2024.17.53102
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →